miravirsen
Nucleic acidexperimental
Miravirsen is an experimental drug for the treatment of hepatitis C, being developed by Santaris Pharma. As of 2017 it was in Phase II clinical trials. — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00688012)
Timeline
Indications
Mechanism of action
- microRNA 122ANTISENSE INHIBITOR
microRNA 122 antisense inhibitor
Antisense inhibitor of miR-122, a microRNA required for replication of HCV in hepatocytes.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMiravirsen ↗
- ChEMBLCHEMBL2108360 ↗
Also known as
- miravirsen
- miravirsen
- miravirsen
- miravirsen
- spc3649
- spc3649
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01872936 | Phase 2 | Jun 1, 2013 | Santaris Pharma A/S |
| NCT01727934 | Phase 2 | Nov 1, 2012 | Fundacion de Investgacion de Diego, Santaris Pharma A/S |
| NCT01646489 | Phase 1 | Jun 1, 2012 | Santaris Pharma A/S, Spaulding Clinical Research Inc. |
| NCT01200420 | Phase 2 | Sep 1, 2010 | J. W. Goethe University, Santaris Pharma A/S |
| NCT00979927 | Phase 1 | Sep 1, 2009 | Pharmaceutical Research Associates, Inc. (PRA), Santaris Pharma A/S |
| NCT00688012 | Phase 1 | May 1, 2008 | Santaris Pharma A/S |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Santaris Pharma A/S | For profit | 6 | 6 | 2 | 2008 |
| Fundacion de Investgacion de Diego | Academic/Hospital | 1 | 0 | 1 | 2012 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2009 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1